# Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

> **NCT04423926** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 91 (estimated)

## Conditions studied

- PTCL, NOS
- AITL
- ALK- ALCL
- Phase III-IV ALK+ ALCL
- EATL

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT04423926
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-10
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423926, "Lenalidomide in Combination With CHOP in Patients With Untreated PTCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04423926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*